Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response

International Journal of Laboratory Hematology

Volumn 30, Issue 4, 2008, Pages 317-323

  Qin, Y Z ^a   Liu, Y R ^a   Zhu, H H ^a   Li, J L ^a   Ruan, G R ^a   Zhang, Y ^a   Jiang, Q ^a   Jiang, H ^a   Li, L D ^a   Chang, Y ^a   Huang, X J ^a   Chen, S S ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b NONE   (China)

Author keywords

BCR ABL, imatinib; Chronic myeloid leukemia; Real time quantitative PCR

Indexed keywords

BCR ABL PROTEIN; IMATINIB; RECOMBINANT ALPHA INTERFERON; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG TREATMENT FAILURE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; METAPHASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CHROMOSOME ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PROGNOSIS; REMISSION;

ADOLESCENT; ADULT; AGED; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 53449085542     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00962.x     Document Type: Article

References (17)

1. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., Delabesse E., Macintyre E., Gottardi E., Saglio G., Watzinger F., Lion T., van Dongen J.J., Hokland P. & Gabert J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse - transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17, 2474-2486.
2. Branford S., Rudzki Z., Harper A., Grigg A., Taylor K., Durrant S., Arthur C., Browett P., Schwarer A.P., Ma D., Seymour J.F., Bradstock K., Joske D., Lynch K., Gathmann I. & Hughes T.P. (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17, 2401-2409.
3. Cortes J., Giles F., O'Brien S., Thomas D., Garcia-Manero G., Rios M.B., Faderl S., Verstovsek S., Ferrajoli A., Freireich E.J., Talpaz M. & Kantanrjian H. (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosomepositive chronic myeloid leukemia after failure of interferon-alpha. Blood 102, 83-86.
4. Daley G.Q., van Etten R.A. & Baltimore D. (1990) Induction of chronic myeloid leukemia by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830.
5. Deininger M.W., Goldman J.M. & Melo J.V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
6. Emig M., Saussele S., Wittor H., Reiter A., Willer A., Berger U., Hehlmann R., Cross N.C.P. & Hochhaus A. (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13, 1825-1832.
7. Gabert J., Beillard E., van der Velden V.H.J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cave H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., Gonzalez M., Viehmann S., Malec M., Saglio G. & van Dongen J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 17, 2318-2357.
8. Hughes T. & Branford S. (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews 20, 29-41.
9. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M. & Radich J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 349, 1423-1432.
10. Iacobucci I., Rosti G., Amabile M., Poerio A., Soverini S., Cilloni D., Testoni N., Abruzzese E., Montefusco E., Ottaviani E., Iuliano F., Russo D., Gobbi M., Alimena G., Martino B., Terragna C., Pane F., Saglio G., Baccarani M. & Martinelli G. (2006) Comparison between patients with Philadelphia- positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. Journal of Clinical Oncology 24, 454-459.
11. Kantarjian H.M., O'Brien S., Cortes J.E., Shan J., Giles F.J., Rios M.B., Faderl S.H., Wierda W.G., Ferrajoli A., Verstovsek S., Keating M.J., Freireich E.J. & Talpaz M. (2003) Complete cytogenetic and molecular responses to interferonalpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97, 1033-1041.
12. Marin D., Kaeda J., Szydlo R., Saunders S., Fleming A., Howard J., Andreasson C., Bua M., Olavarria E., Rahemtulla A., Dazzi F., Kanfer E., Goldman J.M. & Apperley J.F. (2005) Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukemia and prognostic factors for cytogenetic relapse. Leukemia 19, 507-512.
13. Merx K., Muller M.C., Kreil S., Lahaye T., Paschka P., Schoch C., Weisser A., Kuhn C., Berger U., Gschaidmeier H., Hehlmann R. & Hochhaus A. (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16, 1579-1583.
14. Mughal T.I., Yong A., Szydlo R.M., Dazzi F., Olavarria E., van Rhee F., Kaeda J., Cross N.C., Craddock C., Kanfer E., Apperley J. & Goldman J.M. (2001) Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal Haematology 115, 569-574.
15. Muller M.C., Gattermann N., Lahaye T., Deininger M.W., Berndt A., Fruehauf S., Neubauer A., Fischer T., Hossfeld D.K., Schneller F., Krause S.W., Nerl C., Sayer H.G., Ottmann O.G., Waller C., Aulitzky W., le Coutre P., Freund M., Merx K., Paschka P., Konig H., Kreil S., Berger U., Gschaidmeier H., Hehlmann R. & Hochhaus A. (2003) Dynamics of BCR-ABL mRNA expression in firstline therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 17, 2392-2400.
16. Paschka P., Muller M.C., Merx K., Kreil S., Schoch C., Lahaye T., Weisser A., Petzold A., Konig H., Berger U., Gschaidmeier H., Hehlmann R. & Hochhaus A. (2003) Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17, 1687-1694.
17. Wang L., Pearson K., Ferguson J.E. & Clark R.E. (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal Haematology 120, 990-999.